Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 11/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506572 | 0.84 | KDM4E (0.33) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL13557943 | 0.83 | MAP2K1 (0.42) | MAP2K1MAP2K2PARP1 | |
| SCHEMBL6506589 | 0.73 | MAP2K1 (0.36) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL10258263 | 0.73 | L3MBTL1 (0.39) | MAP2K1MAP2K2PARP1 | |
| SCHEMBL13559029 | 0.71 | MAP2K1 (0.41) | MAP2K1MAP2K2 | |
| SCHEMBL14615218 | 0.71 | MAP2K1 (0.45) | MAP2K1MAP2K2PARP1 | |
| SCHEMBL13558506 | 0.70 | MAP2K1 (0.40) | MAP2K1MAP2K2 | |
| SCHEMBL6470190 | 0.70 | PARP1 (0.38) | PARP1ALDH1A1 | |
| SCHEMBL6500386 | 0.70 | PARP1 (0.45) | PARP1 | |
| SCHEMBL10266967 | 0.70 | MAP2K1 (0.43) | MAP2K1MAP2K2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | MAP2K1 4663/4885MAP2K2 4197/4885PARP1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.